Could your own immune cells keep liver cancer from coming back?

NCT ID NCT07709299

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intravenous infusions over two months. The study includes up to 6 participants with early-stage liver cancer who have had their tumor removed, and follows them for six months to monitor side effects and early signs of recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a patient's own immune cells (cytokine-induced killer cells) grown in a lab and given back as infusions
What this could lead to
If safe and feasible, this approach could offer a new way to reduce the risk of liver cancer returning after surgery.
What could go wrong
This is a very early, small trial with only 6 participants, so results may not apply broadly. The treatment could cause side effects or fail to prevent cancer recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Liver Transplant and Surgery Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences

    Tehran, Tehran Province, Iran

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.